Results 61 to 70 of about 62,013 (267)

Trans‐Fistula Contrast‐Enhanced Ultrasound in Diagnosing a Complex Anal‐Bartholin‐Perineal Fistula of Crohn's Disease: A Case Report

Journal of Clinical Ultrasound, EarlyView.
This case illustrates the potential utility of TF‐CEUS as a valuable adjunct in diagnosing complex fistulae. When MRI demonstrates limited sensitivity in detecting complex fistulae, TF‐CEUS can be chosen as a complementary imaging modality. It allows for real‐time, dynamic monitoring of the fistula branches, providing favorable conditions for early ...
Dilimire Abuliezi, Yuan Luo, Qin Huang, Yin Yang, Hua Zhuang   +4 more
wiley   +1 more source

Periodontitis and high phosphate intake alone or in combination adversely affect the kidney

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis and high phosphate (HP) intake can negatively affect the kidney in the presence of renal disease. This study aimed to evaluate the effects of periodontitis or HP intake, either alone or concurrently, on the periodontal tissue and the kidney under normal renal conditions.
Ae Ri Kim, Min Seo Kim, Jiwon Seo, Eun‐Jung Bak, Yun‐Jung Yoo   +4 more
wiley   +1 more source

A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab early colectomy

Therapeutic Advances in Chronic Disease, 2019
Background: Early intervention for acute severe ulcerative colitis (ASUC) improves outcomes. Outcomes and healthcare costs for an infliximab-first and colectomy-first approach were compared.
Abhinav Vasudevan, Asiri Arachchi, Cian Scanlon, Jarrod Greenhalgh, Daniel R. Van Langenberg   +4 more
doaj   +1 more source

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

Respiratory Medicine Case Reports, 2016
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction.
Ying Zhou, Elyse E. Lower, Huiping Li, Robert P. Baughman   +3 more
doaj   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

Gut and Liver, 2015
Background/AimsIn patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission.
doaj   +1 more source

Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease. [PDF]

Clin Pharmacol Ther
Model‐informed precision dosing (MIPD) utilizes pharmacokinetic/pharmacodynamic (PK/PD) models to optimize drug therapy. However, conventional MIPD often requires manual simulation and regimen selection, which are time‐consuming and demand specialized expertise.
Irie K, Minar P, Reifenberg J, Boyle BM, Noe JD, Hyams JS, Mizuno T.   +6 more
europepmc   +2 more sources

Therapy de‐escalation in pediatric patients with inflammatory bowel disease in remission: Data analysis from the CEDATA registry

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives There are no standardized criteria about stepping down from combination therapy (immunomodulator and tumor necrosis factor (TNF)‐alpha‐inhibitors) in children with inflammatory bowel disease (IBD) to reduce risk for side effects. Our aim was to describe how de‐escalation has been performed in a large pediatric cohort and to find ...
Sila Cekin, Christoph Huenseler, Serdar Cantez, Ilse Broekaert, Jan de Laffolie, CEDATA‐GPGE® Study Group   +5 more
wiley   +1 more source

Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease

Case Reports in Ophthalmology, 2010
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease.
Junko Ikewaki, Hirofumi Kono, Kei Shinoda, Toshiaki Kubota, Kazuo Nakatsuka   +4 more
doaj   +1 more source

Fatigue in pediatric inflammatory bowel disease: Explained by transdiagnostic and disease‐focused factors

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Fatigue is highly prevalent in children with inflammatory bowel disease (IBD), even during clinical remission. This suggests a role for transdiagnostic factors—lifestyle, psychological, and social influences not specific to the disease.
Maartje D. Stutvoet, Anouk Vroegindeweij, Tessa Z. Toonen, Merel M. Nap‐Van der Vlist, Johanna W. Hoefnagels, Anemone van den Berg, Sanne L. Nijhof   +6 more
wiley   +1 more source